C
Jazz Pharmaceuticals plc
JAZZ
$138.81
$2.361.73%
C
Hold
12/13/2024Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C from C- on 12/13/2024 due to a noticeable increase in the valuation index, growth index and volatility index. Earnings per share increased from $2.4911 to $3.4204, EBIT increased 30.47% from $199.44M to $260.21M, and operating cash flow increased 20.34% from $331.35M to $398.75M.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C from C- on 12/13/2024 due to a noticeable increase in the valuation index, growth index and volatility index. Earnings per share increased from $2.4911 to $3.4204, EBIT increased 30.47% from $199.44M to $260.21M, and operating cash flow increased 20.34% from $331.35M to $398.75M.
C
Hold
10/16/2024Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C- from D+ on 10/16/2024 due to an increase in the volatility index, total return index and valuation index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C- from D+ on 10/16/2024 due to an increase in the volatility index, total return index and valuation index.
D
Sell
8/2/2024Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 8/2/2024 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 1,253.15% from -$14.62M to $168.57M, earnings per share increased from -$0.2337 to $2.4911, and EBIT increased 89.67% from $105.15M to $199.44M.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 8/2/2024 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 1,253.15% from -$14.62M to $168.57M, earnings per share increased from -$0.2337 to $2.4911, and EBIT increased 89.67% from $105.15M to $199.44M.
D
Sell
5/3/2024Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 5/3/2024 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $1.4221 to -$0.2337, EBIT declined 55.17% from $234.55M to $105.15M, and total revenue declined 10.87% from $1.01B to $901.98M.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 5/3/2024 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $1.4221 to -$0.2337, EBIT declined 55.17% from $234.55M to $105.15M, and total revenue declined 10.87% from $1.01B to $901.98M.
D
Sell
11/9/2023Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from E+ on 11/9/2023 due to a significant increase in the growth index, efficiency index and valuation index. Earnings per share increased from $1.5164 to $2.1423, net income increased 40.58% from $104.44M to $146.82M, and EBIT increased 9.36% from $157.64M to $172.39M.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from E+ on 11/9/2023 due to a significant increase in the growth index, efficiency index and valuation index. Earnings per share increased from $1.5164 to $2.1423, net income increased 40.58% from $104.44M to $146.82M, and EBIT increased 9.36% from $157.64M to $172.39M.
E
Sell
10/12/2023Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to E+ from D- on 10/12/2023 due to a noticeable decline in the volatility index and total return index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to E+ from D- on 10/12/2023 due to a noticeable decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/8/2023Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D- from D on 02/08/2023.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D- from D on 02/08/2023.
D
Sell
2/3/2023Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 2/3/2023 due to a decline in the total return index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 2/3/2023 due to a decline in the total return index.
D
Sell
1/19/2023Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 1/19/2023 due to an increase in the volatility index and total return index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 1/19/2023 due to an increase in the volatility index and total return index.
D
Sell
11/10/2022Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 11/10/2022 due to a significant decline in the efficiency index and solvency index. Net income declined 156.68% from $34.67M to -$19.65M, debt to equity increased from 1.89 to 2.09, and total capital declined 8.11% from $9.32B to $8.56B.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 11/10/2022 due to a significant decline in the efficiency index and solvency index. Net income declined 156.68% from $34.67M to -$19.65M, debt to equity increased from 1.89 to 2.09, and total capital declined 8.11% from $9.32B to $8.56B.
D
Sell
1/7/2022Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 1/7/2022 due to an increase in the volatility index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 1/7/2022 due to an increase in the volatility index.
D
Sell
12/21/2021Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 12/21/2021 due to a decline in the total return index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 12/21/2021 due to a decline in the total return index.
D
Sell
12/6/2021Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 12/6/2021 due to an increase in the volatility index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to D+ from D on 12/6/2021 due to an increase in the volatility index.
D
Sell
11/17/2021Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 11/17/2021 due to a large decline in the total return index, solvency index and volatility index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D from D+ on 11/17/2021 due to a large decline in the total return index, solvency index and volatility index.
D
Sell
8/20/2021Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D+ from C- on 8/20/2021 due to a decline in the volatility index and total return index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D+ from C- on 8/20/2021 due to a decline in the volatility index and total return index.
C
Hold
8/5/2021Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C- from B- on 8/5/2021 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 398.21% from $121.83M to -$363.32M, earnings per share declined from $2.09 to -$6.1115, and operating cash flow declined 85.37% from $285M to $41.7M.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C- from B- on 8/5/2021 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 398.21% from $121.83M to -$363.32M, earnings per share declined from $2.09 to -$6.1115, and operating cash flow declined 85.37% from $285M to $41.7M.
B
Buy
8/2/2021Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 8/2/2021 due to an increase in the total return index and valuation index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 8/2/2021 due to an increase in the total return index and valuation index.
C
Hold
7/2/2021Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C+ from B- on 7/2/2021 due to a decline in the valuation index and volatility index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C+ from B- on 7/2/2021 due to a decline in the valuation index and volatility index.
B
Buy
6/8/2021Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 6/8/2021 due to an increase in the volatility index and total return index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 6/8/2021 due to an increase in the volatility index and total return index.
C
Hold
5/6/2021Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 5/6/2021 due to a significant increase in the valuation index, growth index and total return index. Operating cash flow increased 53% from $186.27M to $285M.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 5/6/2021 due to a significant increase in the valuation index, growth index and total return index. Operating cash flow increased 53% from $186.27M to $285M.
C
Hold
10/20/2020Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C from C- on 10/20/2020 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$2.8207 to $2.06, EBIT increased 35.24% from $148.72M to $201.13M, and total revenue increased 5.18% from $534.73M to $562.44M.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C from C- on 10/20/2020 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$2.8207 to $2.06, EBIT increased 35.24% from $148.72M to $201.13M, and total revenue increased 5.18% from $534.73M to $562.44M.
C
Hold
8/5/2020Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C- from D+ on 8/5/2020 due to an increase in the total return index and volatility index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C- from D+ on 8/5/2020 due to an increase in the total return index and volatility index.
D
Sell
5/20/2020Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D+ from C- on 5/20/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $1.2833 to -$2.8207, net income declined 313.31% from $73.99M to -$157.83M, and total revenue declined 8.08% from $581.74M to $534.73M.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to D+ from C- on 5/20/2020 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $1.2833 to -$2.8207, net income declined 313.31% from $73.99M to -$157.83M, and total revenue declined 8.08% from $581.74M to $534.73M.
C
Hold
4/6/2020Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C- from C on 4/6/2020 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 73.99% from $337.5M to $87.8M, EBIT declined 37.18% from $184.88M to $116.15M, and earnings per share declined from $1.78 to $1.2833.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C- from C on 4/6/2020 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 73.99% from $337.5M to $87.8M, EBIT declined 37.18% from $184.88M to $116.15M, and earnings per share declined from $1.78 to $1.2833.
C
Hold
2/25/2020Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C from C+ on 2/25/2020 due to a decline in the total return index and volatility index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C from C+ on 2/25/2020 due to a decline in the total return index and volatility index.
C
Hold
2/18/2020Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C+ from B- on 2/18/2020 due to a decline in the volatility index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C+ from B- on 2/18/2020 due to a decline in the volatility index.
B
Buy
1/27/2020Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 1/27/2020 due to a noticeable increase in the total return index and volatility index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 1/27/2020 due to a noticeable increase in the total return index and volatility index.
C
Hold
1/13/2020Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 1/13/2020 due to an increase in the volatility index, valuation index and efficiency index. Total capital increased 1.57% from $4.75B to $4.83B.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 1/13/2020 due to an increase in the volatility index, valuation index and efficiency index. Total capital increased 1.57% from $4.75B to $4.83B.
C
Hold
12/6/2018Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C from C+ on 12/6/2018 due to a decline in the volatility index and valuation index.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C from C+ on 12/6/2018 due to a decline in the volatility index and valuation index.
C
Hold
11/19/2018Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C+ from B- on 11/19/2018 due to a decline in the growth index and volatility index. Total revenue declined 6.22% from $500.48M to $469.37M, and EBIT declined 3.73% from $196.1M to $188.78M.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C+ from B- on 11/19/2018 due to a decline in the growth index and volatility index. Total revenue declined 6.22% from $500.48M to $469.37M, and EBIT declined 3.73% from $196.1M to $188.78M.
B
Buy
9/28/2018Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 9/28/2018 due to an increase in the volatility index, solvency index and valuation index.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to B- from C+ on 9/28/2018 due to an increase in the volatility index, solvency index and valuation index.
C
Hold
8/9/2018Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 8/9/2018 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 123.33% from $87.81M to $196.1M, earnings per share increased from $0.75 to $1.5, and operating cash flow increased 18.02% from $162.36M to $191.62M.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 8/9/2018 due to a significant increase in the growth index, total return index and volatility index. EBIT increased 123.33% from $87.81M to $196.1M, earnings per share increased from $0.75 to $1.5, and operating cash flow increased 18.02% from $162.36M to $191.62M.
C
Hold
5/10/2018Downgrade
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C from C+ on 5/10/2018 due to a substantial decline in the growth index, total return index and valuation index. Earnings per share declined from $3.795 to $0.75, EBIT declined 41.15% from $149.21M to $87.81M, and operating cash flow declined 20.63% from $204.56M to $162.36M.
Jazz Pharmaceuticals plc (JAZZ) was downgraded to C from C+ on 5/10/2018 due to a substantial decline in the growth index, total return index and valuation index. Earnings per share declined from $3.795 to $0.75, EBIT declined 41.15% from $149.21M to $87.81M, and operating cash flow declined 20.63% from $204.56M to $162.36M.
C
Hold
4/6/2018Upgraded
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 4/6/2018 due to a noticeable increase in the total return index, valuation index and solvency index. Debt to equity declined from 0.64 to 0.58, and the quick ratio increased from 2.65 to 2.81.
Jazz Pharmaceuticals plc (JAZZ) was upgraded to C+ from C on 4/6/2018 due to a noticeable increase in the total return index, valuation index and solvency index. Debt to equity declined from 0.64 to 0.58, and the quick ratio increased from 2.65 to 2.81.
C
Hold
9/29/2017Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from C+ on 9/29/2017 due to a decline in the total return index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from C+ on 9/29/2017 due to a decline in the total return index.
C
Hold
9/14/2017Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to C+ from C on 9/14/2017 due to an increase in the solvency index, total return index and volatility index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to C+ from C on 9/14/2017 due to an increase in the solvency index, total return index and volatility index.
C
Hold
8/11/2017Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from C+ on 8/11/2017 due to a decline in the total return index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from C+ on 8/11/2017 due to a decline in the total return index.
C
Hold
5/15/2017Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to C+ from C on 5/15/2017 due to an increase in the volatility index, total return index and efficiency index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to C+ from C on 5/15/2017 due to an increase in the volatility index, total return index and efficiency index.
C
Hold
3/28/2017Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to C from C- on 3/28/2017 due to a significant increase in the growth index, total return index and efficiency index. Earnings per share increased from $1.41 to $2.0294, net income increased 42.62% from $87.15M to $124.28M, and operating cash flow increased 32.35% from $136.53M to $180.7M.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to C from C- on 3/28/2017 due to a significant increase in the growth index, total return index and efficiency index. Earnings per share increased from $1.41 to $2.0294, net income increased 42.62% from $87.15M to $124.28M, and operating cash flow increased 32.35% from $136.53M to $180.7M.
C
Hold
1/3/2017Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C- from C on 1/3/2017 due to a substantial decline in the growth index, total return index and solvency index. Debt to equity increased from 0.7 to 1.27, the quick ratio declined from 5.06 to 2.85, and earnings per share declined from $1.8 to $1.41.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C- from C on 1/3/2017 due to a substantial decline in the growth index, total return index and solvency index. Debt to equity increased from 0.7 to 1.27, the quick ratio declined from 5.06 to 2.85, and earnings per share declined from $1.8 to $1.41.
C
Hold
10/20/2016Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from C+ on 10/20/2016 due to a decline in the volatility index and total return index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from C+ on 10/20/2016 due to a decline in the volatility index and total return index.
C
Hold
3/11/2016Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C+ from B+ on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Operating cash flow declined 31.61% from $175.08M to $119.74M, and earnings per share declined from $1.39 to $1.32.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C+ from B+ on 3/11/2016 due to a significant decline in the volatility index, growth index and total return index. Operating cash flow declined 31.61% from $175.08M to $119.74M, and earnings per share declined from $1.39 to $1.32.
B
Buy
1/22/2016Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B+ from B on 1/22/2016 due to an increase in the volatility index, valuation index and total return index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B+ from B on 1/22/2016 due to an increase in the volatility index, valuation index and total return index.
B
Buy
1/7/2016Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B from A- on 1/7/2016 due to a noticeable decline in the total return index and volatility index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B from A- on 1/7/2016 due to a noticeable decline in the total return index and volatility index.
A
Buy
12/31/2015Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to A- from B+ on 12/31/2015 due to a noticeable increase in the total return index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to A- from B+ on 12/31/2015 due to a noticeable increase in the total return index.
B
Buy
11/13/2015Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B+ from B on 11/13/2015 due to an increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 0.94 to 0.82, and total capital increased 1.42% from $2.81B to $2.85B.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B+ from B on 11/13/2015 due to an increase in the valuation index, efficiency index and solvency index. Debt to equity declined from 0.94 to 0.82, and total capital increased 1.42% from $2.81B to $2.85B.
B
Buy
11/6/2015Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B from B+ on 11/6/2015 due to a decline in the valuation index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B from B+ on 11/6/2015 due to a decline in the valuation index.
B
Buy
11/4/2015Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B+ from A- on 11/4/2015 due to a major decline in the volatility index and total return index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B+ from A- on 11/4/2015 due to a major decline in the volatility index and total return index.
A
Buy
8/26/2015Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to A- from B+ on 8/26/2015 due to an increase in the valuation index and solvency index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to A- from B+ on 8/26/2015 due to an increase in the valuation index and solvency index.
B
Buy
8/10/2015Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B+ from B on 8/10/2015 due to a large increase in the growth index, solvency index and valuation index. Operating cash flow increased 45.59% from $96.56M to $140.57M, EBIT increased 30.51% from $117.47M to $153.3M, and earnings per share increased from $1.12 to $1.4.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B+ from B on 8/10/2015 due to a large increase in the growth index, solvency index and valuation index. Operating cash flow increased 45.59% from $96.56M to $140.57M, EBIT increased 30.51% from $117.47M to $153.3M, and earnings per share increased from $1.12 to $1.4.
B
Buy
5/8/2015Upgraded
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B from C on 5/8/2015 due to a significant increase in the growth index, valuation index and total return index.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was upgraded to B from C on 5/8/2015 due to a significant increase in the growth index, valuation index and total return index.
C
Hold
5/9/2014Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from B on 5/9/2014 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from $0.8899 to -$1.5831, EBIT declined 15.49% from $101.88M to $86.1M, and operating cash flow declined 13.24% from $79.21M to $68.72M.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to C from B on 5/9/2014 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from $0.8899 to -$1.5831, EBIT declined 15.49% from $101.88M to $86.1M, and operating cash flow declined 13.24% from $79.21M to $68.72M.
B
Buy
2/28/2014Downgrade
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B from A- on 2/28/2014 due to a substantial decline in valuation and growth. Operating cash flow declined 38.98% from $129.8M to $79.21M, earnings per share declined from $1.23 to $0.8899, and EBIT declined 4.06% from $106.19M to $101.88M.
Jazz Pharmaceuticals Public Limited Company (JAZZ) was downgraded to B from A- on 2/28/2014 due to a substantial decline in valuation and growth. Operating cash flow declined 38.98% from $129.8M to $79.21M, earnings per share declined from $1.23 to $0.8899, and EBIT declined 4.06% from $106.19M to $101.88M.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
